Alembic Therapeutics

Alembic is a clinical-stage biotechnology company pioneering the field of precision nutrition to enhance the efficacy of targeted cancer therapies. Founded by world-renowned oncology researchers Siddhartha Mukherjee, Lewis Cantley, and Karen Vousden, the company focuses on the metabolic interplay between systemic insulin levels and tumor growth. Their primary approach involves combining PI3K inhibitors with specific dietary interventions designed to suppress the insulin feedback loop that often leads to drug resistance. By modulating the patient's systemic metabolism, Alembic aims to transform the therapeutic window and durability of treatments for PIK3CA-mutant cancers. The company is currently validating its integrated drug-diet platform through clinical trials in various solid tumor indications.